MULTIPLE sclerosis (MS) is an autoimmune neurological condition diagnosed in 3.5 to 6.6 people per 100,000 of the population each year — equivalent to between 1,800 and 3,400 people in England and Wales. It is mostly diagnosed between the ages of 20 and 40 years and there are roughly ...
Treatment options Medications for Multiple Sclerosis Care guides Multiple Sclerosis Medicine.com guides (external) Multiple Sclerosis Guide Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.Medical...
The aim is to develop a model to estimate the benefit of alternative treatment options for individual patients. Henc... K Chalkou,E Steyerberg,M Egger,... 被引量: 0发表: 2020年 Recent Advances in the Treatment for Multiple Sclerosis; Current New Drugs Specific for Multiple Sclerosis Since ...
Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2.5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these drugs are unable to halt or reverse the diseas...
Cognitive impairment is a common and devastating manifestation of multiple sclerosis (MS). Although disease-modifying therapies have been efficacious for reducing relapse rates in MS, such treatments are ineffective for treating cognitive dysfunction. Al
Early aggressive treatment approaches for multiple sclerosis. Curr Treat Options Neurol. 2021;23(7):19. doi:10.1007/s11940-021-00677-1PubMedGoogle ScholarCrossref 25. Spelman T, Magyari M, Piehl F, et al. Treatment escalation vs immediate initiation of highly effective ...
With the availability of disease-modifying, immunomodulatory therapies (DMT) for multiple sclerosis (MS) and the first long-term studies, it became obvious that problems of compliance to complex treatment regimens under chronic conditions would also apply to these approaches. In a selective overview,...
OBJECTIVE: The aim of the present study was to provide data on the use of immunomodulatory therapies in a population comprising all treated patients with relapsing-remitting multiple sclerosis (RRMS) in Denmark. PATIENTS AND METHODS: From the introduction of immunomodulatory therapy in Denmark in 1996...
Learn about OCREVUS® (ocrelizumab), a prescription medicine used for multiple sclerosis (MS) treatment in adults with relapsing or primary progressive multiple sclerosis, available in 3 different administration options: a 4-hour infusion, a 2-hour inf
Aconcussionor whiplash can cause migraine, and so canstroke, lesions frommultiple sclerosis (MS), and infections. All of these can damage the brain so that neurons are firing sporadically or continuously in a pathological manner, generating the symptoms of a migraine. ...